Schrödinger Acquires XTAL BioStructures
January 14, 2022
Schrödinger, Inc. acquired XTAL BioStructures, Inc., a Natick, Massachusetts–based structural biology services provider, in an all-cash transaction that closed January 14, 2022 for $6 million. The acquisition brings protein production, purification, biophysical methods and X-ray crystallography capabilities in‑house to support Schrödinger's structure-based drug discovery platform and expand its experimental offerings for customers.
- Buyers
- Schrödinger, Inc.
- Targets
- XTAL BioStructures, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Calibre Scientific Acquires NeXtal Biotechnologies from Qiagen
January 8, 2020
Biotechnology
Calibre Scientific has acquired the NeXtal Biotechnologies line of structural biology products (including EasyXtal crystallization plates) from Qiagen NV. The purchase expands Calibre's structural biology and protein crystallization product portfolio, supplying academic, biotechnology, and pharmaceutical customers.
-
Ligand Pharmaceuticals Acquires Crystal Bioscience
October 4, 2017
Biotechnology
Ligand Pharmaceuticals acquired Crystal Bioscience for $25 million in cash plus up to $10.5 million in milestones and revenue sharing, adding Crystal's chicken-derived HuMab (OmniChicken) antibody discovery platform and an in-house discovery lab. The acquisition (closing announced Oct 4, 2017) brings four fully-funded partnership programs, is expected to be accretive to revenue and earnings, and expands Ligand's OmniAb platform capabilities.
-
NuChem Sciences Acquires IniXium
October 31, 2022
Biotechnology
Montreal-based contract research organization NuChem Sciences has acquired IniXium of Laval, Québec, with investment support from the Fonds de solidarité FTQ. The deal expands NuChem's structural biology and recombinant protein production capabilities—integrating IniXium's crystallography and fragment screening expertise into NuChem's drug-discovery services.
-
Bruker Corporation Acquires NanoString Technologies Business
May 6, 2024
Medical Devices
Bruker Corporation has acquired substantially all assets of NanoString Technologies, Inc. through a court-supervised Chapter 11 asset sale for approximately $392.6 million in cash plus assumption of certain liabilities. The deal, announced April 2024 and closed in late April/early May 2024, brings NanoString's spatial biology and gene-expression product lines into Bruker to preserve customer access, product development, and jobs while expanding Bruker's life‑science instrumentation capabilities.
-
ZS Acquires Intomics A/S
May 4, 2022
Biotechnology
ZS, a global professional services firm, has acquired Copenhagen-based bioinformatics and systems biology company Intomics A/S. The 42-person team and Intomics' curated protein-protein interaction network and analytics capabilities will expand ZS's drug discovery, bioinformatics and R&D offerings to better serve pharmaceutical, biotech and research clients.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.